魯軍
一、個人簡介
魯軍，成都中醫(yī)藥大學(xué)教授/博士生導(dǎo)師；香港浸會大學(xué)中醫(yī)藥學(xué)院博士/博士后，任職于成都中醫(yī)藥大學(xué)藥學(xué)院。四川省高層次引進(jìn)人才，省部級優(yōu)秀人才計(jì)劃入選者，四川省杰出青年科技人才。在Nature Aging, Nature Communications, European Journal of Medicinal Chemistry, Pharmacological Research等國際期刊發(fā)表SCI論文50余篇，申請多項(xiàng)中國和美國發(fā)明專利并已授權(quán)專利8項(xiàng)。主持國家自然基金面上項(xiàng)目、青年項(xiàng)目、四川省杰出青年基金及地區(qū)基金10余項(xiàng)。
聯(lián)系方式：ljaaa111@163.com
研究方向：
1藥物化學(xué)及藥物遞送方向
靶向抗腫瘤功能性大分子（包括核酸、多肽、多糖等具有特殊功能性的大分子）-活性天然藥物偶聯(lián)物的設(shè)計(jì)、合成以及藥理學(xué)評價；
多功能自組裝納米藥物的設(shè)計(jì)、合成以及藥理學(xué)評價。
2 有機(jī)化學(xué)及藥物合成方向
基于增效減毒的目的，對具有潛在生物活性的中藥單體成分或是高毒性的天然藥物成分進(jìn)行結(jié)構(gòu)修飾，獲取新型藥物分子，并進(jìn)行藥理學(xué)評價；
基于手性小分子催化劑，開發(fā)新型催化劑以及構(gòu)建新的合成方法，用于建立具有開發(fā)和應(yīng)用前景的藥物分子庫。
3 藥理學(xué)方向
針對腫瘤、炎癥等相關(guān)疾病開發(fā)的新型藥物分子或是活性天然產(chǎn)物，評價其生物活性并闡明作用機(jī)制。
二、代表性成果（可含承擔(dān)項(xiàng)目、發(fā)表論文、論著、獲獎等）
1.國家自然科學(xué)基金委員會，面上項(xiàng)目，82273812，核酸適配體-多價喜樹堿偶聯(lián)物的設(shè)計(jì)、合成及其EGFR介導(dǎo)的靶向抗腫瘤活性研究，2023-01-01至2026-12-31，在研，主持
2.四川省自然科學(xué)基金，杰出青年科學(xué)基金，23NSFJQ0099，GSH驅(qū)動智能型EGFR核酸適配體多價喜樹堿偶聯(lián)物“精準(zhǔn)狙擊”非小細(xì)胞肺癌的研究，2023-01至 2026-12，在研，主持
2021~2022年代表作：
1.Yiru Pu, Yi Zuo, Jie Ling, Meimei Li, Hui Huang, Jun Lu*. Carbene-catalyzed kinetic resolution of bispirooxindoles: selective lactam amidation and access to challenging chiral scaffolds. Organic Chemistry Frontiers.
2.Yao Chen, Jirui Yang, Yi Zuo, Chaozheng Zhang, Yiru Pu, Qing Ren, Xiao Li, Yunqian Huang, Hui Huang, Huan Yang, Ouyang You, Xila Xia, Aiping Lu, Sanjun Shi, Yun Deng, Jun Lu*. Voacamine is a novel inhibitor of EGFR exerting oncogenic activity against colorectal cancer through the mitochondrial pathway. Pharmacological Research, 2022, 184, 106415.
3.Meimei Li, Hui Huang, Wanrong Tian, Yiru Pu, Yun Deng, Jun Lu*. A close look into the biological and synthetic aspects of fused pyrazole derivatives. European Journal of Medicinal Chemistry, 2022: 114739.
4.Meimei Li, Hui Huang, Wanrong Tian, Yiru Pu, Chaozheng Zhang, Jirui Yang, Qing Ren, Feiyan Tao, Yun Deng, Jun Lu*. Construction of multi-substituted pyrazoles via potassium carbonate-mediated [3+2] cycloaddition of in situ generated nitrile imines with cinnamic aldehydes. RSC advances, 2022, 12, 13087-13092.
5.Yi Zuo, Chaozheng Zhang, Qing Ren, Yao Chen, Xiao Li, Jirui Yang, Hongxiang Li, Wentao Tang, Hingman HO, Chen Sun, Meimei Li, Bo Ren, Yun Deng, Maolin Wang, Jun Lu*. Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression. Phytomedicine, 2022, 99, 154015.
6.Qing Ren, Meimei Li, Yun Deng, Aiping Lu, Jun Lu*. Triptolide delivery: nanotechnology-based carrier systems to enhance efficacy and limit toxicity. Pharmacological Research, 2021, 165, 105377.
7.Meimei Li, Yun Deng, Jun Lu*. Dracaenone, a Novel Type of Homoisoflavone: Natural Source, Biological Activity and Chemical Synthesis[J]. Current Organic Chemistry, 2022, 26, 887-897.
8.Yuzhi Wang, Zhaohai Pan, Xiaolan Cheng, Kai Zhang, Xin Zhang, Yao Qin, Jiaojiao Fan, Ting Yan, Tao Han, Kwok Keung Shiu, Sam Chun-KitHau, Nai KiMak, Daniel W.J.Kwong, Xiaona Liu, Minjing Li, Guowei Deng, Qiusheng Zheng, Jun Lu*, Defang Li*. A red-light-activated sulfonamide porphycene for highly efficient photodynamic therapy against hypoxic tumor. European Journal of Medicinal Chemistry. 2021, 209, 11286.
9.Zhaohai Pan, Jiaojiao Fan, Qi Xie, Xin Zhang, Wen Zhang, Qing Ren, Minjing Li, Qiusheng Zheng, Jun Lu*, Defang Li*. Novel sulfonamide porphyrin TBPoS-2OH used in photodynamic therapy for malignant melanoma. Biomedicine & Pharmacotherapy, 2021, 133, 111042.
10.Meimei Li, Xiaozhen Chen, Yun Deng, Jun Lu*. Recent advances of N-heterocyclic carbenes in the applications of constructing carbo-and heterocyclic frameworks with potential biological activity. RSC advances, 2021, 11, 38060-38078.
11.Maolin Wang, Xingsheng Shu, Meiqi Li, Yilin Zhang, Youli Yao, Xiaoyan Huang, Jianna Li, Pengfei Wei, Zhendan He, Jun Lu*, Ying Ying*. Novel Strategy Conjugating PD-L1 Polypeptide with Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer. Frontiers in oncology, 2021, 11, 737323.
12.Jin Liu#, Xiaohao Wu#, Jun Lu#, Guangxin Huang#, Lei Dang, Huarui Zhang, Chuanxin Zhong, Zongkang Zhang, Dijie Li, Fangfei Li, Chao Liang, Yuanyuan Yu, Bao-Ting Zhang, Lin Chen, Aiping Lu, Ge Zhang Exosomal transfer of osteoclast-derived miRNAs to chondrocytes contributes to osteoarthritis progression. Nature Aging, 2021, 1, 1-17.